好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Experimental Improvement of Attention / Cognitive Speed Does Not Improve Memory in Multiple Sclerosis
Multiple Sclerosis
P13 - Poster Session 13 (8:00 AM-9:00 AM)
3-001

To investigate whether atomoxetine (FDA-approved to improve attention) versus placebo improves memory in persons with MS.
Correlational studies link memory performance with attention and cognitive speed in persons with MS, which has led to the belief that inattention or slowed cognitive speed underlie MS memory deficits. This assumption has shaped memory rehabilitation approaches, which have been ineffective. Herein we used data from a pilot cross-over trial of atomoxetine in persons with MS to examine whether experimentally improving attention and cognitive speed improves memory.
Ten persons with MS with objective memory impairment (mean[sd] normative z: -1.86[0.55]) completed a double-blind randomized controlled crossover trial of atomoxetine (80mg daily) versus placebo for 14 weeks (two counterbalanced six-week phases separated by two-week washout). Primary memory outcome (MEMORY) was a composite of the Selective Reminding Test and Brief Visuospatial Memory Test, Revised. Patients also completed CANTAB Rapid Visual Information Processing (RVP) assessing sustained attention and cognitive speed during a six-minute continuous performance task requiring persons to monitor single-digit numbers rapidly presented onscreen to identify target three-digit sequences (e.g., 3-5-7). Paired two-tailed t-tests compared outcomes (norm-referenced z-scores) between placebo and drug after adjusting for counterbalanced order.
Improvement on RVP (attention / cognitive speed) from baseline was better on atomoxetine (mean[sd] z change: +0.57[0.48]) than placebo (+0.25[0.29]; t[9]=3.96, p=0.003, d=0.72). In contrast, change from baseline on MEMORY did not differ between atomoxetine (+0.32[0.76]) and placebo (+0.24[0.70]; t[9]=0.40, p=0.700, d=0.10).
Experimental improvement of attention / cognitive speed with atomoxetine did not improve memory in persons with MS, which refutes correlational evidence linking these functions. We lack validated memory rehabilitation approaches, perhaps in part because attention / cognitive speed have been treatment targets. Renewed investigation of underlying mechanisms of MS memory impairment is necessary to develop strategies for memory rehabilitation.
Authors/Disclosures
Emily Dvorak
PRESENTER 		Ms. Dvorak has nothing to disclose.
Ilana B. Katz Sand, MD (Corinne Goldsmith Dickinson Center for MS) The institution of Dr. Katz Sand has received research support from National Multiple Sclerosis Society. The institution of Dr. Katz Sand has received research support from Hirschl Foundation. The institution of Dr. Katz Sand has received research support from National Institutes of Health. Dr. Katz Sand has received personal compensation in the range of $500-$4,999 for serving as a Conference presenter with 好色先生.
James F. Sumowski (Icahn School of Medicine At Mount Sinai) Mr. Sumowski has nothing to disclose.